NEWS
Mar 27, 2026

SSRP Institute Welcomes Medivive as New Trusted Partner

PARTNER ANNOUNCEMENT

WILLOUGHBY, Ohio, [March 27, 2026] — The SSRP Institute is pleased to announce that Medivive has joined its Trusted Partner Network following nomination and internal vetting aligned with SSRP’s mission of advancing science-first, education-driven clinical collaboration.

Medivive offers an advanced approach to NAD⁺ therapy designed to support cellular energetics through sterile, clinician-prescribed formulations produced under current Good Manufacturing Practices (cGMP) and dispensed by licensed pharmacies. Delivered subcutaneously, Medivive’s NAD⁺ therapy is designed to improve bioavailability compared to oral precursors while supporting tissue energy production and redox balance under medical supervision.

Jay Palmer, CEO and Co-Founder of Medivive says, "Dr. Seeds and I have known each other for a while, and when we started talking about what Medivive was building, the fit was obvious. SSRP practitioners hold their protocols to a high standard, and the Medivive pen was built to match it. This is the first prefilled NAD+ subcutaneous injector pen manufactured to cGMP standards at a 503B outsourcing facility in the US. Drug-grade testing on every batch, delivered the right way, with zero burden on the practice. We are proud to be the preferred NAD+ provider for this community." 

"Now, we can feel more confident in measuring and following the evidence on this with a safe product,” Dr. William Seeds, Founder and Academic Chairman of the SSRP Institute said recently on Episode 50 of his podcast, Redox Revolution. “This really opens the door to some powerful things you can start doing as you work to help that patient. I mean, it's things that I have not been able to do for a very long time.”

Certificates of Analysis covering potency, sterility, and endotoxin testing are maintained for every batch and are available to prescribers upon request. Medivive’s dedicated Partner Page is now live and provides SSRP Members with information about their offerings, research background, and ways they support clinical practice.

For more information and to view the Medivive Partner Page, visit:
SSRP Medivive Partner Page


About the SSRP Institute

The SSRP Institute is an education-focused organization dedicated to advancing cellular medicine through evidence-based training, professional collaboration, and clinically relevant research. SSRP supports providers worldwide through certifications, events, and ongoing educational programming designed to improve patient outcomes and elevate the standard of care.

The SSRP Trusted Partner Network is invitation-only and based on real-world clinical relevance, thoughtful nomination, and alignment with SSRP’s educational principles. Partners are integrated through a structured process designed to foster collaboration, support clinician education, and strengthen the implementation of cellular medicine practices.

RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
BREAKING NEWS August 26, 2026 – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Aug 24, 2026
Ep. 102 - Office Hours: PWC26 Virtual Summit Part 4
Preview Only
Office Hours PWC26 Virtual Summit Part 4 – Episode 102

Office Hours PWC26 Virtual Summit Part 4- Episode 102

  1. Compounded topical creams and GHK-Cu with microneedling (0:59)
  2. Detoxing before using copper (12:09)
  3. Patient onboarding process (12:54)
  4. Zinc and iron supplementation with GHK-Cu (23:41)
  5. Loss of taste after COVID (25:55)
  6. 3D CT scans for root canals (27:03)
  7. Oral bacteria swabs and GLP-1 effectiveness (28:00)
  8. Endocannabinoid system (29:07)
  9. GHK-Cu efficacy on wound beds (32:05)

Preview Only — Become a member for full access
SSRP Institute Aug 21, 2026
Alpha-Gal Syndrome: An Update on Incidence Rate by the CDC
HEADLINE SCIENCE JAMA recently published a report about the incidence rate of alpha-gal syndrome, which is a serious allergic reaction to a sugar molecule called alpha-gal, which is found in most mammals. It is typically transmitted through a bite from a Lone Star tick or other tick species that injects the molecule into the body, […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Aug 17, 2026
Ep. 101 - Office Hours: PWC26 Virtual Summit Part 3
Preview Only
Office Hours PWC26 Virtual Summit Part 3 – Episode 101

Office Hours PWC26 Virtual Summit Part 3 – Episode 101

1. Mitochondrial peptides (1:07)
2. MOTS-c cycle (3:50)
3. Injury site specific injection (9:25)
4. BPC-157 dosing (15:18)
5. Trusted labs (20:56)
6. What “redox” means (25:48)
7. Patient with cervical fusion, pain, and decreased range of motion (31:36)
8. Lipedema (37:03)
9. SS-31 and MOTS-c (37:52)
10. NanoVI device (44:49)
11. NAD (48:13)

Preview Only — Become a member for full access
IntellxxDNA Aug 12, 2026
SSRP Institute Welcomes IntellxxDNA as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [August 12, 2026] — The SSRP Institute welcomes IntellxxDNA to its Trusted Partner Network following a nomination and internal vetting process, aligning with SSRP’s mission to advance science-first, education-driven clinical collaboration. IntellxxDNA provides clinicians with a structured genomic decision support platform that translates complex genetic data into clinically actionable insights. Using […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Aug 10, 2026
Ep. 100 - Office Hours: PWC26 Virtual Summit Part 2
Preview Only
Office Hours PWC26 Virtual Summit Part 2 – Episode 100

Office Hours PWC26 Virtual Summit Part 2 – Episode 100

  1. Evaluating terrain of the patient (1:43)
  2. SS31 peptide in practice (8:50)
  3. Phenotyping the right patient for GLP-1 therapy (11:18)

 

Preview Only — Become a member for full access
ARTICLE
William Seeds, MD
Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
William Seeds, MD Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
Mitochondrial dysfunction is one of the most firmly established hallmarks of aging, but the field has spent far more energy describing genetic causes of mitochondrial failure—mtDNA mutation, defective OXPHOS, impaired unfolded protein response—than the “natural” drivers that erode mitochondria during ordinary aging. As I discussed in my recent June Journal Club (as well as a […]
READ ARTICLE
VIDEO
Cellular Medicine Mondays
Aug 3, 2026
Ep. 099 - Office Hours: PWC26 Virtual Summit Part 1
Preview Only
Office Hours: PWC26 Virtual Summit Part 1 – Episode 099

Office Hours: PWC26 Virtual Summit Part 1 – Episode 099

This special edition of Office Hours features questions submitted during the Peptide World Congress Virtual Summit on July 10 and 11. Dr. Seeds and Dr. Newman address:

  1. GLOW Stack, MOTS c, and Thyroid Function (0:50)
  2. Should the GLOW Stack Be Separated? (3:31)
  3. Peptides in Transplant Medicine (8:02)
  4. Biomarker Monitoring (13:21)
  5. Peptides in Acute and Long Term Stroke Recovery (17:37)
  6. Autoimmunity and the GI Tract (23:00)
  7. Cancer Concerns Related to Hormones and Angiogenesis (26:49)

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Jul 27, 2026
Ep. 098 - Pentosan Polysulfate: Dosing, Safety, and Monitoring
Preview Only
Dissecting Protocols – Episode 098

Pentosan Polysulfate: Dosing, Safety, and Monitoring

Dr. Seeds examines the subcutaneous use of pentosan polysulfate, addressing concerns about injection site scarring and ocular safety. He discusses dosing, site rotation, cumulative exposure, retinal screening, and strategies for responsible, individualized treatment.(Question Link)

Preview Only — Become a member for full access
SSRP Institute Jul 24, 2026
PCAC Meeting Vote Summary
BREAKING NEWS JULY 24, 2026 – The Pharmacy Compounding Advisory Committee (PCAC) has completed its July session, voting on several peptide bulk drug substances for potential inclusion on the FDA’s 503A Bulks List.Recommended FOR inclusion: (Yes-No)• BPC-157 (8–6)• KPV (8–6)• TB-500 (8–6)• MOTS-c (7–5)• Epitalon (7–4)• Semax (8–5)Recommended AGAINST inclusion: (Yes-No)• DSIP (6–7) What happens […]
READ NEWS

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.